Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Australian medtech firm Orthocell recorded its strongest U.S. month for Remplir™, selling 92 units of the FDA-cleared collagen nerve wrap in October 2026.
Australian medical device maker Orthocell Ltd reported its highest single-month U.S. sales total for its Remplir™ collagen nerve wrap since the product's commercial launch, with 92 units sold in October 2026, according to a company announcement.
Remplir™ is an FDA-cleared device engineered to support the repair and protection of peripheral nerves. Designed and manufactured in Australia, the wrap is positioned by the company as an emerging category leader in key international markets, reflecting a broader push by smaller medtech firms to capture share in the nerve repair segment.
Read more Mumtalakat and ARP Group to Launch AI-Native Wholesale Bank in Bahrain →
The October milestone underscores growing clinical adoption of the product in the United States, one of the world's largest markets for surgical device innovation. Sustained monthly volume gains are typically a closely watched indicator for early-stage commercial medtech products seeking to establish reimbursement pathways and expand their surgeon user base.
Orthocell's progress with Remplir™ signals continued momentum for the Perth-based company as it scales its international commercial operations. The nerve repair market has drawn increased attention from both established players and smaller innovators, given rising demand driven by trauma surgery, oncological reconstruction, and diabetic neuropathy-related procedures.
Continue reading at All Financial Services & Investing.
